Tevogen Bio Announces 1-for-50 Reverse Stock Split

Tevogen Bio Holdings ( (TVGN) ) has shared an announcement.

On March 3, 2026, Tevogen Bio Holdings Inc. filed a Certificate of Amendment in Delaware to implement a 1-for-50 reverse stock split of its common stock, effective March 6, 2026, following shareholder approval on February 19, 2026. The move will reduce the roughly 202.4 million outstanding shares proportionally without changing authorized share count or relative ownership stakes, aside from minor adjustments due to cash in lieu of fractional shares.

Tevogen’s board approved the split to help the company regain compliance with Nasdaq’s $1.00 minimum bid price requirement, with trading to begin on a split-adjusted basis under the unchanged TVGN ticker and a new CUSIP. All equity awards, warrants, and convertible preferred stock will be adjusted to reflect the new share ratio, leaving the company’s underlying operations and total stockholders’ equity unchanged but potentially stabilizing its listing status and market perception.

The most recent analyst rating on (TVGN) stock is a Sell with a $0.26 price target. To see the full list of analyst forecasts on Tevogen Bio Holdings stock, see the TVGN Stock Forecast page.

Spark’s Take on TVGN Stock

According to Spark, TipRanks’ AI Analyst, TVGN is a Neutral.

The score is driven primarily by very weak financial performance (no revenue, ongoing losses, negative free cash flow, and negative equity), which outweighs the benefit of lower debt. Technicals add further pressure with a strong downtrend and negative MACD, while valuation metrics offer limited support due to a negative P/E and no dividend yield.

To see Spark’s full report on TVGN stock, click here.

More about Tevogen Bio Holdings

Tevogen Bio Holdings Inc. is a socially integrated healthcare enterprise focused on affordability, efficiency, and scientific rigor in advanced therapeutics. The company leverages artificial intelligence and precision T cell therapy platforms through its Tevogen Bio and Tevogen.AI initiatives to develop treatments in virology, oncology, neurology, and scalable solutions for the broader healthcare system.

Tevogen Bio has completed a proof-of-concept clinical trial for its single-HLA-restricted, genetically unmodified allogeneic T cells, built on its proprietary ExacTcell platform. Tevogen.AI aims to accelerate drug development and target detection using predictive technologies and cloud-based data services, while the company also explores future strategic moves in generics, biosimilars, medical devices, and innovative insurance solutions to expand patient access.

Average Trading Volume: 946,067

Technical Sentiment Signal: Sell

Current Market Cap: $49.92M

See more data about TVGN stock on TipRanks’ Stock Analysis page.